Actavis and Zydus settle with Supernus over seizure drug

Speciality pharmaceutical company Supernus has settled patent disputes over Trokendi XR (topiramate), a treatment for partial seizures, with US-based Zydus Pharmaceuticals and Actavis Laboratories.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Zydus challenges ruling in Takeda antitrust dispute

16 June 2022 Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.

Americas

Supernus hits Zydus with repeat suit over migraine drug

20 September 2021 Supernus Pharmaceuticals has once again accused Indian generic drugmaker Zydus Cadila and its US unit of allegedly infringing 10 patents with its copycat of Trokendi XR (topiramate), a drug for migraines and seizures.

Americas

Takeda v Zydus: FTC intervenes in sham lawsuit claims

11 June 2018 The US Federal Trade Commission has filed an amicus brief urging a district court to reject Takeda’s claim that its patent infringement lawsuit brought under the Hatch-Waxman Act cannot be a sham.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Actavis and Zydus settle with Supernus over seizure drug

More on this story

Editor's picks

Editor's picks

More features